EDMONTON, Jan. 25, 2012 /CNW/ - Medwell Capital Corp. ("Medwell") (TSXV: MWC) announced today that pursuant to its stock option plan the Company has granted options to directors, officers, employees and consultants entitling them to purchase up to 3,305,000 common shares at a price of $0.13 per share on or before January 3, 2021.
For further information please visit www.medwellcapital.com.
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Medwell, and anticipated events or results, are assumptions based on beliefs of Medwell's senior management as well as information currently available to it. While these assumptions were considered reasonable by Medwell at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Medwell to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information:
For further information about Medwell please contact: